[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"pituitary-tumor\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:pituitary-tumor":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,9,0,[8,41,64,92,112,135,157,202,227],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":21,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100639504","net-time-inflammatory-tumor-microenvironment-in-pituitary-neoplasm-100639504",false,"NCT07594262","NET-TIME: Inflammatory Tumor Microenvironment in Pituitary Neoplasm","Inflammatory Tumor Microenvironment in Pituitary Neoplasm","NET-TIME","Inclusion Criteria:\n\n* indication as per clinical practice and in agreement to current guidelines for surgical removal of the PitNET0;\n* patient naïve to medical therapy before surgical removal of PitNET;\n* Diagnosis of PitNET confirmed through the study pathological\u002Fhistological;\n* over 18 years of age;\n* acceptance of participation in the study, by signing an informed consent.\n\nExclusion Criteria:\n\n* History of medical therapy with analogs of somatostatin or dopamine agonist, previous the removal of the pituitary adenoma;\n* history of radiotherapy of the head and neck region earlier than 10 years after resection of the adenoma pituitary;\n* history of autoimmune diseases.",true,"ALL","18 Years","100 Years",{"count":22,"type":23},60,"ESTIMATED","OBSERVATIONAL","Over the past twenty years, a progressively increasing number of markers biochemical, clinical, imaging, histopathological or genetic have been suggested to attempt to predict aggression and therapeutic outcome, both in secretory PitNETs and in non-secretory PitNETs. In recent years, the microenvironment tumor (TEM) has been extensively studied in different malignancies, promoting the development of therapies target and immunotherapy with checkpoint inhibitors immune system (ICI). Data on TIME in PitNETs are scarce today and derive from studies conducted mainly on heterogeneous cases for type of PitNET. Therefore, the purpose of this research project is to investigate the TIME in PitNET, to identify immune biomarkers and new molecular pathways that can promote the use of ICI and target therapies in Aggressive PitNETs.",[27],"Pituitary Tumor","RECRUITING","2026-05-14",{"date":31,"type":32},"2026-05-18","ACTUAL",{"date":34,"type":32},"2023-06-03",{"date":36,"type":23},"2027-03-31",{"name":38,"class":39},"Fondazione Policlinico Universitario Agostino Gemelli IRCCS","OTHER",1,{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":4,"eligibilityCriteria":47,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":48,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":50,"conditions":51,"keywords":52,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":55,"lastUpdatePostDateStruct":56,"startDateStruct":58,"completionDateStruct":60,"leadSponsor":62,"locationsCount":40},"100102642","pituitary-tumor-surveillance-pathogenic-correlation-100102642","NCT00599092","Pituitary Tumor Surveillance: Pathogenic Correlation","Pituitary Tumor Surveillance: Pathogenetic Correlation","Inclusion Criteria:\n\n* patients with confirmed pituitary disease\n\nExclusion Criteria:\n\n* patients who do not have confirmed pituitary disease",{"count":49,"type":23},1250,"The purpose of this study is to observe predictors of pituitary tumor recurrence and markers of persistent disease activity in patients harboring pituitary mass lesions of all types.",[27],[53,54],"pituitary tumor","recurrence","2026-03-19",{"date":57,"type":32},"2026-03-23",{"date":59,"type":4},"1997-01",{"date":61,"type":23},"2050-12",{"name":63,"class":39},"Cedars-Sinai Medical Center",{"id":65,"slug":66,"hasResults":11,"nctId":67,"briefTitle":68,"officialTitle":69,"acronym":4,"eligibilityCriteria":70,"healthyVolunteers":11,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":71,"targetDuration":4,"studyType":73,"phases":74,"briefSummary":76,"conditions":77,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":83,"lastUpdatePostDateStruct":84,"startDateStruct":86,"completionDateStruct":88,"leadSponsor":90,"locationsCount":40},"100449960","evaluation-of-the-convivo-system-100449960","NCT05139277","Evaluation of the CONVIVO System","Clinical Investigation to Evaluate the CONVIVO System for Discrimination of Normal From Abnormal Tissue During Brain Tumor Resection","Inclusion Criteria:\n\n* Adult patients (age\\>18)\n* Adults presenting with suspected intracranial gliomas (including glioblastoma), cerebral metastasis, meningiomas, acoustic neuromas, and pituitary adenomas, who are surgical candidates\n* Adults able to provide informed consent.\n\nExclusion Criteria:\n\n* Pregnancy\n* Children (age \\\u003C18 years)\n* Fluorescein sodium (FNa) allergy",{"count":72,"type":23},30,"INTERVENTIONAL",[75],"NA","The primary objective of this study is to evaluate the diagnostic performance of the CONVIVO confocal endomicroscope in discriminating between normal and abnormal tissue in vivo during brain tumor surgery. The interpretation of intraoperative images obtained in situ will be tested against conventional histologic evaluation of targeted biopsies from imaged tissue. The study team hypothesize that there will be a high degree of correlation between images obtained with the CONVIVO system and conventional histologic interpretation.",[78,79,80,81,82,27],"Glioblastoma","Glial Tumor","Brain Metastases","Meningioma","Schwannoma","2026-02-04",{"date":85,"type":32},"2026-02-06",{"date":87,"type":32},"2022-06-28",{"date":89,"type":23},"2026-10",{"name":91,"class":39},"Dartmouth-Hitchcock Medical Center",{"id":93,"slug":94,"hasResults":11,"nctId":95,"briefTitle":96,"officialTitle":96,"acronym":4,"eligibilityCriteria":97,"healthyVolunteers":11,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":98,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":99,"conditions":100,"keywords":4,"overallStatus":102,"whyStopped":4,"lastUpdateSubmitDate":103,"lastUpdatePostDateStruct":104,"startDateStruct":106,"completionDateStruct":108,"leadSponsor":110,"locationsCount":40},"100536601","perimetry-based-on-eye-movements-in-patients-with-suprasellar-tumors-100536601","NCT06266949","Perimetry Based on Eye-movements in Patients With (Supra)Sellar Tumors","Inclusion Criteria:\n\n* Diagnosed with a (supra)sellar tumor\n* Visual field loss based on the most recent SAP; False positive rate \\\u003C15%; fixation losses \\\u003C20%\n* Informed written consent\n\nExclusion Criteria:\n\n* Neurological disorders\n* Eye disease not related to a (supra)sellar tumor",{"count":72,"type":23},"The purpose of this study is to assess wether the SONDA visual field test is suitable for patients with a supra sellar tumour.",[27,101],"Visual Fields Hemianopsia","NOT_YET_RECRUITING","2025-05-01",{"date":105,"type":32},"2025-05-02",{"date":107,"type":23},"2025-08-01",{"date":109,"type":23},"2026-08-01",{"name":111,"class":39},"University Medical Center Groningen",{"id":113,"slug":114,"hasResults":11,"nctId":115,"briefTitle":116,"officialTitle":116,"acronym":4,"eligibilityCriteria":117,"healthyVolunteers":11,"sex":18,"minAge":19,"maxAge":118,"enrollmentInfo":119,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":121,"conditions":122,"keywords":123,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":126,"lastUpdatePostDateStruct":127,"startDateStruct":129,"completionDateStruct":131,"leadSponsor":133,"locationsCount":40},"100570268","differential-study-of-invasive-pituitary-adenomas-in-the-sellar-and-cavernous-sinus-regions-100570268","NCT06705036","Differential Study of Invasive Pituitary Adenomas in the Sellar and Cavernous Sinus Regions","Inclusion Criteria:\n\n1. Invasive pituitary tumors involving the cavernous sinus\n2. Retrospective inclusion of patients who have signed informed consent forms for the donation of biological samples and health-related information\n3. Age range: 18-80 years\n4. Subjects are willing to participate in this study\n\nExclusion Criteria:\n\n1. Non-invasive pituitary tumors\n2. Pregnant or breastfeeding\n3. Other conditions deemed unsuitable for participation in this clinical trial as assessed by the physician","80 Years",{"count":120,"type":23},20,"This study involves collecting paired tumor samples from intrasellar and cavernous sinus regions of 20 invasive pituitary tumor patients, preserving them at -80°C for quality multi-omics analysis. Proteomics and transcriptomics are employed to identify molecular differences, while imaging data (MRI\u002FCT) assesses tumor morphology and invasion. In vitro experiments and mechanistic studies validate key findings, exploring how regional molecular differences affect tumor behavior. Data integration combines multi-omics and imaging features to uncover biomarkers and pathways associated with invasiveness and regional specificity, with statistical analysis ensuring significance and reliability.",[27],[124,125],"cavernous sinus","intrasellar","2024-11-23",{"date":128,"type":32},"2024-11-26",{"date":130,"type":32},"2024-11-01",{"date":132,"type":23},"2026-12-31",{"name":134,"class":39},"Shanghai Zhongshan Hospital",{"id":136,"slug":137,"hasResults":11,"nctId":138,"briefTitle":139,"officialTitle":139,"acronym":4,"eligibilityCriteria":140,"healthyVolunteers":11,"sex":18,"minAge":141,"maxAge":142,"enrollmentInfo":143,"targetDuration":4,"studyType":73,"phases":145,"briefSummary":146,"conditions":147,"keywords":148,"overallStatus":102,"whyStopped":4,"lastUpdateSubmitDate":149,"lastUpdatePostDateStruct":150,"startDateStruct":152,"completionDateStruct":154,"leadSponsor":155,"locationsCount":4},"100558827","surgical-and-pharmacological-efficacy-of-knosp-grade-0-2-prolactinoma-100558827","NCT06556186","Surgical and Pharmacological Efficacy of Knosp Grade 0-2 Prolactinoma","Inclusion Criteria:\n\n* Prolactin level greater than three times the normal upper limit\n* MRI indicates Knosp Grade 0-2 pituitary adenoma\n\nExclusion Criteria:\n\n* MRI indicates Knosp grade 3-4 pituitary adenoma\n* Taking antidepressants or other psychotropic drugs\n* Patients allergic to bromocriptine or cannot tolerate surgery\n* Women defined as surgical infertility (i.e. hysterectomy, bilateral salpingectomy, or bilateral oophorectomy), or amenorrhea for more than 2 years\n* Critical illness patients, such as those with progressive consciousness disorders, cerebral hernias, and other emergency situations","20 Years","40 Years",{"count":144,"type":23},600,[75],"The investigators carried out a multi-center comparative study, involving hospitals including the Second Affiliated Hospital of Zhejiang University School of Medicine, Peking Union Medical College Hospital, West China Hospital, Wenzhou First Hospital, and Li Huili Hospital. This study aimed to compare the efficacy of medication and surgery for specific subtypes of microadenomas and clearly defined macroadenomas (Knosp grades 0-2), in order to determine which is more effective and which has fewer benefits, thereby enhancing the evidence base.",[27],[53],"2024-08-13",{"date":151,"type":32},"2024-08-15",{"date":153,"type":23},"2024-10-01",{"date":36,"type":23},{"name":156,"class":39},"Second Affiliated Hospital, School of Medicine, Zhejiang University",{"id":158,"slug":159,"hasResults":11,"nctId":160,"briefTitle":161,"officialTitle":161,"acronym":4,"eligibilityCriteria":162,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":163,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":165,"conditions":166,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":192,"lastUpdatePostDateStruct":193,"startDateStruct":195,"completionDateStruct":197,"leadSponsor":199,"locationsCount":201},"100556321","genetic-bases-of-neuroendocrine-neoplasms-in-mexican-patients-100556321","NCT06523582","Genetic Bases of Neuroendocrine Neoplasms in Mexican Patients","Inclusion Criteria:\n\nAdult patients with a new or previous clinical diagnosis of any of the following conditions:\n\n* Isolated NENs with sporadic presentation, including bronchopulmonary NENs, gastrointestinal NENs, medullary thyroid carcinoma, pancreatic NENs, paragangliomas, pheochromocytomas, pituitary neuroendocrine tumors, and primary hyperparathyroidism.\n* Familial isolated NENs, including familial isolated pituitary adenoma, familial pheochromocytomas and paragangliomas, familial primary hyperparathyroidism, familial gastrointestinal stromal tumors and X-linked acrogigantism.\n* Clinical syndromes encompassing NENs, with familial or sporadic presentation, including Carney complex, Carney-Stratakis syndrome, Carney triad, Cowden syndrome, DICER1 syndrome, Li-Fraumeni syndrome, Lynch syndrome, multiple endocrine neoplasia type 1, multiple endocrine neoplasia type 2, multiple endocrine neoplasia type 4, neurofibromatosis type 1, Pacak-Zhuang syndrome, paraganglioma, pheochromocytoma and pituitary adenoma syndrome, tuberous sclerosis complex, Von Hippel Lindau syndrome.\n\nExclusion criteria:\n\n* Age \\\u003C18 years.\n* Refusal to give informed consent.",{"count":164,"type":23},750,"Neuroendocrine neoplasms (NENs) are a heterogeneous group of lesions derived from cells with the ability to produce hormones that may arise from multiple different organs. Their clinical behavior is quite variable, encompassing both benign lesions and aggressive tumors that invade surrounding and\u002For distant structures. NENs may also cause serious morbidity due to hormone oversecretion. NENs are among the most frequently inherited human tumors, presenting either isolated or as part of syndromes in which a single patient or family develops multiple tumors. There are also non-inherited changes in the genetic information of the tumor cells that are potential targets for treatment. Both inherited and non-inherited DNA defects can be identified using modern routine genetic tests which, unfortunately, are not widely available in Mexico.\n\nThis project seeks to uncover the genetic defects causing NENs in a large cohort of Mexican patients, using three different methods for genetic testing. Adult individuals with various types of NENs from two reference hospitals in Mexico City will be invited to participate. After completing informed consent, blood and, if possible, tissue samples will be obtained from all participants. Clinical details, laboratory results, imaging studies, and histopathological data at disease presentation will be retrieved.\n\nAn initial screening will be performed by analyzing changes in the sequence of multiple genes that have been associated with the occurrence of NENs. In cases with negative screening, a specific method to assess changes in the number of copies of the same genes will also be employed. Finally, sequences of all DNA regions encoding information required to make proteins will be obtained in selected cases. Analyses will be carried out in blood and, if available, also in tumor tissue samples from study participants. Screening of additional family members will be offered.\n\nThis project will accurately describe the repertoire of specific defects causing NENs in the study population, and will likely uncover and characterize novel genetic associations. The results will contribute for a better understanding of the alterations within and outside known driver genes that shape syndromic presentations, tumor behaviors, and inheritance patterns in individuals with NENs. These data will contribute to improve the information on the molecular bases of NENs, including alterations that can be used as therapeutic targets.",[167,168,169,170,171,172,173,174,175,176,27,177,178,179,180,181,182,183,184,185,186,187,188,189,190,191],"Neuroendocrine Neoplasm","Neuroendocrine Neoplasm of Gastrointestinal Tract","Neuroendocrine Neoplasm of Lung","Thymic Neuroendocrine Neoplasm","Neuroendocrine Tumor of Pancreas","Gastrointestinal Stromal Tumors","Medullary Thyroid Cancer","Paraganglioma","Pheochromocytoma","Primary Hyperparathyroidism","Multiple Endocrine Neoplasia Type 1","Multiple Endocrine Neoplasia Type 2","Multiple Endocrine Neoplasia Type 4","Carney Complex","Carney Stratakis Dyad","Carney Triad","Cowden Syndrome","DICER1 Syndrome","Li-Fraumeni Syndrome","Lynch Syndrome","Von Hippel-Lindau Disease","Familial Isolated Pituitary Adenoma","X-Linked Acrogigantism","Neurofibromatosis 1","Tuberous Sclerosis","2024-07-22",{"date":194,"type":32},"2024-07-26",{"date":196,"type":32},"2022-08-03",{"date":198,"type":23},"2037-03-01",{"name":200,"class":39},"Universidad Nacional Autonoma de Mexico",3,{"id":203,"slug":204,"hasResults":11,"nctId":205,"briefTitle":206,"officialTitle":207,"acronym":4,"eligibilityCriteria":208,"healthyVolunteers":11,"sex":18,"minAge":141,"maxAge":4,"enrollmentInfo":209,"targetDuration":4,"studyType":73,"phases":210,"briefSummary":211,"conditions":212,"keywords":214,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":218,"lastUpdatePostDateStruct":219,"startDateStruct":221,"completionDateStruct":223,"leadSponsor":225,"locationsCount":40},"100552393","using-polyglycolic-acid-mesh-prevents-cerebrospinal-fluid-leakage-100552393","NCT06472505","Using Polyglycolic Acid Mesh Prevents Cerebrospinal Fluid Leakage","Using Polyglycolic Acid Mesh Prevents Cerebrospinal Fluid Leakage: Clinical Application to Endoscopic Endonasal Transsphenoidal Surgery","A. Inclusion criteria\n\n1\\. Patients with primary or recurrent pituitary tumors require endoscopic nasal surgery.\n\nB. Exclusion criteria\n\n1. Patients with pituitary gland tumors who do not receive surgical treatment.\n2. Patients with other brain tumors.\n3. Patients allergic to polyglycolic acid (PGA).\n4. Patients who have had previous radiation therapy or chemotherapy.",{"count":72,"type":23},[75],"The papers propose a new method to prevent postoperative cerebrospinal fluid leakage. Doctors use the absorbable polyglycolic acid (PGA) and fibrin glue to repair in surgery, prevent cerebrospinal fluid leakage and reduce the necessity of postoperative lumbar drainage after surgery. This study will analyze the changes in cerebrospinal fluid leakage in patients with pituitary tumors and skull base tumors after surgery, and further understand the effectiveness of Neoveil , as the basis for the development of new treatments.",[27,213],"Cerebrospinal Fluid Leakage",[215,216,217],"Pituitary tumor","Endoscopic transnasal transsphenoidal","CSF leakage","2024-06-24",{"date":220,"type":32},"2024-06-25",{"date":222,"type":32},"2023-12-01",{"date":224,"type":23},"2025-12-31",{"name":226,"class":39},"National Taiwan University Hospital",{"id":228,"slug":229,"hasResults":11,"nctId":230,"briefTitle":231,"officialTitle":232,"acronym":233,"eligibilityCriteria":234,"healthyVolunteers":11,"sex":18,"minAge":235,"maxAge":236,"enrollmentInfo":237,"targetDuration":4,"studyType":73,"phases":239,"briefSummary":240,"conditions":241,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":242,"lastUpdatePostDateStruct":243,"startDateStruct":245,"completionDateStruct":247,"leadSponsor":249,"locationsCount":251},"100489930","nasal-outcomes-using-saline-irrigations-after-endonasal-pituitary-surgery-100489930","NCT05659524","Nasal Outcomes Using Saline Irrigations After Endonasal Pituitary Surgery","Nasal Outcomes Using Saline Irrigations After Endonasal Pituitary Surgery - The NOSE Trial","NOSE","Inclusion criteria\n\n1. Adult patient undergoing endoscopic surgery for resection of pituitary tumors\n\n   * nonfunctioning adenoma\n   * acromegaly\n   * prolactinoma\n   * Rathke's cleft cyst\n2. Adults \\>18 and \\\u003C85 years of age\n3. English speaking and able to understand the ASK Nasal-12 and SNOT-22 scales\n4. Free of any physical, mental, or medical condition which, in the opinion of the investigator, makes study participation inadvisable\n5. Planned binostril surgical approach\n6. Either with or without septal flap reconstruction\n7. Either with or without septoplasty\n\nExclusion criteria\n\n1. Active sinus infection\n2. Allergic rhinitis\n3. Asthma\n4. Vascular or inflammatory disease\n5. History of previous sinonasal surgery\n6. Any subject who is unwilling or unable to sign informed consent for the study\n7. Pregnancy\n8. Incarcerated patients\n9. Cushing's disease\n10. History of chronic sinusitis\n11. Extended approaches to the skull base\n12. Active sinusitis\n13. Nasal polyps\n14. Concurrent antibiotics for another indication (i.e., urinary tract infection)\n15. Immunodeficiency\n16. History of radiation to the skull base","19 Years","85 Years",{"count":238,"type":23},140,[75],"This is a prospective, single-blinded, multicenter study evaluating the benefit of sinonasal irrigations following endoscopic pituitary surgery. The goal of this study is to create practice changing guidelines with objective data highlighting the importance of irrigations on postoperative outcomes for pituitary surgery.",[27],"2024-04-17",{"date":244,"type":32},"2024-04-19",{"date":246,"type":32},"2020-12-18",{"date":248,"type":23},"2029-12-31",{"name":250,"class":39},"Lori Wood",2]